Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death.

Area of Science:

• Biomedical Engineering
• Immunology
• Oncology

Background:

• Cancer immunotherapy faces challenges from low immunogenicity and immunosuppressive tumor microenvironments.
• Immunogenic cell death (ICD) inducers can enhance immunotherapy by releasing danger signals and antigens, but suffer from toxicity and poor tumor targeting.
• Stimuli-responsive nanoparticles offer a solution to mitigate toxicity and improve delivery of ICD inducers.

Purpose of the Study:

• To review recent advances in stimuli-responsive nanoparticles for cancer immunotherapy.
• To highlight the potential of various stimuli-responsive systems (NIR, pH, redox, etc.) in enhancing ICD-based cancer therapy.
• To evaluate the clinical translation prospects of these nanoparticle-ICD inducer combinations.

Main Methods:

• Review of literature on stimuli-responsive nanoparticles and their application in cancer immunotherapy.
• Categorization of nanoparticles based on their responsiveness (e.g., NIR, pH, redox).
• Analysis of how these systems improve ICD induction and overcome limitations of traditional inducers.

Main Results:

• Stimuli-responsive nanoparticles effectively enhance ICD induction while reducing systemic toxicity.
• Various responsive mechanisms (NIR, pH, redox) demonstrate tailored drug delivery and improved tumor localization.
• Combinations of stimuli-responsive nanoparticles with ICD inducers show significant potential for generating anticancer immunity.

Conclusions:

• Stimuli-responsive nanoparticles represent a promising platform for advancing ICD-based cancer immunotherapy.
• These systems address key challenges of toxicity and targeting, paving the way for improved clinical outcomes.
• Further research and clinical translation of these nanoparticle-ICD inducer strategies are warranted.